IO Biotech

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced an oral presentation and two poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. The invited oral presentation will provide an update on the Phase 1/2 study (MM1636) with IO102-103 in combination with nivolumab for metastatic melanoma. Results from the MM1636 study served as the basis for the FDA granting Breakthrough Therapy Designation and for the Phase 3 trial with IO102-103 in combination with pembrolizumab for metastatic melanoma which is currently enrolling. The two posters will discuss preclinical work on the next two candidates in the IO Biotech pipeline, which target the immunosuppressive effects of Arginase 1 and transforming growth factor beta 1 (TGF-β1).

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that Mai-Britt Zocca, the company's President and CEO, will be participating in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference, taking place September 12 – 14, 2022.

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ending June 30, 2022.

IO Biotech Announces Second Quarter Results for 2022

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the company will be participating at the 2022 BIO International Convention, taking place June 13 – 16, 2022, at the San Diego Convention Center in San Diego, California.

IO Biotech to Participate in the 2022 BIO International Convention

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today two poster presentations highlighting clinical trials in progress with IO102-IO103 as an investigational agent in combination with pembrolizumab in metastatic solid tumors and in untreated, unresectable or metastatic melanoma at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022. The meeting will be held in-person and virtually June 3-7, 2022 in Chicago.

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the Company will be participating in the Jefferies Global Healthcare Conference, to be held June 8-10, 2022, in New York City. Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech will be available to meet with investors in-person on a one-on-one basis throughout the conference.

IO Biotech to Participate in the Jefferies Healthcare Conference

- First Patient Dosed in Proposed Registrational Trial in Melanoma - Multiple Sites to be Opened Across the United States, Australia, and Europe| - Trial Builds upon Phase 1 / 2 Results Recently Published in Nature Medicine

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April -- -- Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-arm basket trial --

IO Biotech Announces First Quarter Results for 2022

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its Phase 2 IOB-022 / KN-D38 trial (NCT05077709).

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today updated efficacy data and subgroup analyses from the MM1636 Phase 1/2 clinical trial evaluating IO102-IO103 as investigational agents in metastatic melanoma in an e-poster presentation at the American Association of Cancer Research conference (AACR), being held April 8-13, 2022 in New Orleans, Louisiana.

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April-- -- Began Patient Recruitment for Global Phase 3 Combination Trial with Lead Asset IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma--

IO Biotech Announces Year-End Results for 2021

Clinical Update from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma from New Data Cut as of December 1, 2021

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to be held virtually March 7 – 9, 2022. At the conference, IO Biotech CEO Dr. Mai-Britt Zocca will participate in the Novel IO Panel Discussion.

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors. Mr. Smith, a veteran biotech executive with over 30 years of experience in executive and financial leadership, will serve on the Audit Committee of the Board.

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

The shares of IO Biotech Inc (NASDAQ: IOBT) have received a $21 price target from Morgan Stanley. These are the details.

IO Biotech (IOBT) Stock: $21 Price Target From Morgan Stanley

WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, including the exercise in full by the underwriters' option to purchase 1,072,500 additional shares of common stock,] at the initial public offering price of $14.00 per share. The gross proceeds to IO Biotech, before deducting underwriting discounts and commissions and offering expenses, were approximately $115.1 million. The shares began trading on The Nasdaq Global Market November 5, 2021, under the symbol "IOBT."

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

WILMINGTON, Del., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the pricing of its initial public offering of 7,150,000 shares of its common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $100.1 million, before deducting underwriting discounts and commissions and offering expenses. The shares are expected to begin trading on The Nasdaq Global Market on November 5, 2021, under the symbol “IOBT.” The offering is expected to close on November 9, 2021, subject to the satisfaction of customary closing conditions. In addition, IO Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

News for IO Biotech Stock (IOBT)